Article Text

Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis
  1. B. Schnabl, Tä1,
  2. S. V. Bettenay, BVSc, DipEd, MACVSc, FACVSc1,
  3. K. Dow1 and
  4. R. S. Mueller, DrMedVet, DrMedVetHabil, MACVSc, DipACVD, FACVSc1
  1. 1Animal Skin and Allergy Clinic, 70 Blackburn Road, Mount Waverley, VIC 3149, Australia


The success of the treatment of 117 dogs with atopic dermatitis with allergen-specific immunotherapy for up to 48 months was assessed. An excellent response (remission with exclusive immunotherapy) was recorded in 18 of the dogs, a good response (more than 50 per cent reduction in medication and improvement of clinical signs) was recorded in 57, a moderate response was recorded in 24 and a poor response in 18. The mould antigens in the allergen extract were stored in a separate vial before administration and the success rate of the immunotherapy including mould antigens was much higher than in an earlier study in which mould and pollen antigens had been stored in one vial. The success rate was not affected significantly by the age of the dogs when the disease developed, or by their age or the period for which they had shown clinical signs when the treatment began; it was also unaffected by whether pollens, moulds or dust mites were used as antigens, or by whether the offending allergens had been identified by intradermal testing or by serum testing for allergen-specific immunoglobulin E.

Statistics from


  • Dr Schnabl’s and Dr Mueller’s present address is Medizinische Tierklinik, Ludwig- Maximilians-Universität, München, Veterinärstrasse 13, 80539 München, Germany

  • Ms Bettenay’s present address is Schäftlarner Weg 1, 82041 Deisenhofen, Germany

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.